Australija - engleski - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 3 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; pregelatinised maize starch; sodium lauryl sulfate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 4000; quinoline yellow aluminium lake; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 2 mg - tablet - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; purified talc; macrogol 4000; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 1 mg - tablet - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; propylene glycol; hyprolose; purified talc - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 0.5 mg - tablet - excipient ingredients: pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide red; macrogol 4000; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - risperidone -

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

asp global, llc - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - fluoride ion 7.6 mg in 1 g - anticavity helps protect against cavities

Malezija - engleski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ranbaxy (malaysia) sdn. bhd. - risperidone -

Irska - engleski - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - sorafenib tosilate - film-coated tablet - sorafenib

Malezija - engleski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ranbaxy (malaysia) sdn. bhd. - risperidone -